To improve quality of life and prevent long-term risks in patients with inflammatory bowel diseases (IBDs: Crohn's disease, ulcerative colitis), it is essential to suppress inflammatory activity adequately. However, corticosteroids are only suitable for therapy of acute flares and the evidence for positive effects of immunosuppressive substances like azathioprine or 6-mercapropurine is mainly limited to maintenance of remission. In addition, only subgroups of patients benefit from biologicals targeting tumour necrosis factor α or α4β7 integrins. In summary, until now the disease activity is not sufficiently controlled in a relevant fraction of the patients with IBD. Thus, there is an urge for the development of new substances in the therapy of ulcerative colitis and Crohn's disease. Fortunately, new oral and parenteral substances are in the pipeline. This review will focus on oral substances, which have already passed phase II studies successfully at this stage. In this article, we summarize data regarding AJM300, phosphatidylcholine (LT-02), mongersen, ozanimod, filgotinib and tofacitinib. AJM300 and ozanimod were tested in patients with ulcerative colitis and target lymphocyte trafficking through inhibition of the α subunit of integrin, respectively binding to the sphingosine-1-phosphate receptor (subtypes 1 and 5) on lymphocytes. Mongersen was utilized in patients with Crohn's disease and accelerates the degradation of SMAD7 mRNA, which consequently strengthens the mainly anti-inflammatory signalling pathway of transforming growth factor β1. Various Janus kinase (JAK) inhibitors were developed, which inhibit the intracellular signalling pathway of cytokines. For example, the JAK1 blocker filgotinib was tested in Crohn's disease, whereas the JAK1/3 inhibitor tofacitinib was tested in clinical trials for both Crohn's disease and ulcerative colitis. A different therapeutic approach is the substitution of phosphatidylcholine (LT-02), which might recover the colonic mucus. Taken together, clinical trials with these new agents have opened avenues for further clinical studies and it can be expected that at least some of these agents will be finally approved for clinical therapy.
Introduction
Inflammatory bowel diseases (IBD) such as ulcerative colitis (UC) and Crohn's disease (CD) have a chronic course. 1, 2 The incidences of these diseases are increasing. 3 Because CD cannot be healed and the only definitive therapy for UC is ileocolectomy, most patients need an anti-inflammatory therapy for life or at least for several decades. 1, 2, 4 Insufficient control of inflammatory activity leads to a marked decrease in a patient's quality of life. 5 In the long term, this situation can result in a higher risk of colon cancer, especially for patients with UC. 6 In the case of CD, strictures with the need for operative resections of the gut can occur, which could finally lead to intra-abdominal adhesions or a short bowel syndrome. 7 However, an optimal therapy should not have serious side effects.
Corticosteroids are very potent in inducing remission, [8] [9] [10] but due to frequent adverse effects (AEs) and lack of efficacy this class of substances is not suitable for long-term use. 11, 12 Mesalamine is the frequent basic therapy for UC, though this substance alone is too weak in many patients with rather severe courses. 13, 14 If there is any positive effect concerning the induction of remission in patients with CD at all, this is very small. 15 Furthermore, it has been suggested that this substance decreases the risk of colorectal cancer in patients with UC. 16 In addition to this, immunosuppressive agents like azathioprine and 6-mercaptopurine can support maintenance of remission in subgroups of patients. [17] [18] [19] [20] After advances in understanding the pathophysiology of IBD, biologicals have been developed in recent years and are now available for patients with IBD in clinical routine. Currently, not only tumour necrosis factor (TNF)-α inhibitors (infliximab, 21, 22 adalimumab, 23, 24 certolizumab pegol 25 and golimumab 26, 27 ), but also the α4β7 integrin inhibitor vedolizumab [28] [29] [30] and the antibody against interleukin (IL)-12 and IL-23 ustekinumab are important parts of the therapy. In addition, in the United States the α4 integrin blocker natalizumab can be used in therapyrefractory patients with CD. 31 However, approximately one third of patients receiving anti-TNFα therapy have no benefit and roughly another third show a secondary loss of efficacy. 32 Thus, the therapeutic success is still limited and in a relevant group of patients inflammatory activity cannot be suppressed sufficiently. 33 Furthermore, the risk of infections and certain types of cancers may be increased by some immunosuppressive substances. 34 Fortunately, we can look forward to new substances at the transition to clinical usage. 33 In the following, we describe new oral substances for the therapy of UC and CD. In this review, we confine ourselves to selected oral drugs, which have been recently developed and successful tested in phase II clinical trials. New parenteral drugs are described and discussed elsewhere. 33 
Substances
Inhibition of the α4 integrin subunit: AJM300 This small molecule inhibitor is directed against the α4 integrin subunit, which is expressed by lymphocytes and is necessary for homing of these cells [ Table 1 , Figure 1(b) ]. 35 Thus, the aim of this therapy is to inhibit the lymphocyte trafficking into the gut. Homing is a highly complex process, which is composed of different steps and is regulated by plenty of receptor interactions. 36 The type of integrin defines the target tissue. For example, α4β7 integrins are mainly responsible for homing of T cells into the gut, 37 whereas α4β1 integrins mediate the migration of lymphocytes to the gut and the brain. 36, 38 The α4β7-integrin antibody vedolizumab has already been successfully established in the therapy of patients with IBD. 39 This was the proof of principle, that targeting lymphocyte trafficking can reduce inflammation in the gut and improve complaints of patients with IBD. The antibody natalizumab, which binds to the α4 integrin subunit, was effective in the therapy of multiple sclerosis 40 and CD. 41, 42 By application of AJM300 to mice, experimental colitis could be prevented. 43 However, inhibition of the α4 integrin subunit by natalizumab also results in a decrease in lymphocyte homing to brain tissue and thus an increased risk for the occurrence of progressive multifocal leukencephalopathy (PML). 44 PML results from a reactivation of the John Cunningham virus (JCV) in patients with a substantially suppressed immune system. 44 This disease has been observed in 2 of 1000 patients with multiple sclerosis after therapy with the antibody natalizumab. 45 PML was also observed during therapy with natalizumab in some patients with CD. 46 The therapeutic efficacy and safety of AJM300 was tested in a randomized, double-blind, placebo-controlled phase IIa study with 102 patients with UC in 2015 in Japan (Table 2) . 35 The substance was given orally for 8 weeks (3 × 960 mg per day) and the primary endpoint was clinical response. The study demonstrated significant improvement in clinical response, endoscopic remission and histological response. The positive effect was observed for extent and duration of disease. No serious AEs (SAEs) occurred in this study; the AEs were mild and self-limiting, and did not markedly differ between drug and placebo groups. However, because of the low number of patients and short time of observation, this study was not able to exclude an association with the rare but often lethal PML. Thus, further studies are necessary to estimate this risk more precisely. In the case of natalizumab, PML occurred less often in patients without antibodies against JCV and within the first 8 months of therapy. 45 Therefore, this potential risk could be markedly reduced by treating only those patients without 
Substitution of phosphatidylcholine: LT02
The colonic epithelial cells are covered by a layer of mucus, which serves as a barrier for microbiota 47 and includes antibacterial substances such as defensins. 60 Phospholipids (mainly phosphatidylcholine) in this mucus could prevent bacteria from invasion. 61 In patients with UC the amount of phosphatidylcholine in colonic mucus is diminished by 70%. 62, 63 It is possible that a primary lack of mucus could facilitate bacterial contact with epithelial cells, which results in intestinal inflammation. 64 Therefore, substitution of phosphatidylcholine in the colonic mucus would be an interesting therapeutic approach ( Table 1 ). 47 
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Primary endpoint
Clinical response In a double-blind, randomized, placebo-controlled phase IIa study 60 patients with UC were treated with 6 g of phosphatidylcholine-rich phospholipids for 3 months ( Table 2 ). The phospholipids were released in the distal ileum in a pH-dependent manner. A significant improvement in comparison with placebo was shown for the primary endpoints clinical remission and clinical response. Moreover, a significant positive effect in endoscopic and histological assessment was observed. 65 Because of these encouraging results, a multicentre phase II study with additional patients with UC (n = 156) was performed. The patients were randomized into three treatment groups with 0.8, 1.6 or 3.2 g of a certain phosphatidylcholine formula (LT-02) or the placebo group. Clinical response after 3 months of therapy was the primary endpoint and reached statistical significance. Clinical remission and endoscopic remission were not significantly different between the treatment and placebo group. In a second analysis, considering dropouts as failures, endoscopic remission but not clinical remission reached statistical significance. The histological remission was significantly more often reached in the treatment group. Within the treatment group no SAEs were observed and there were no deviations concerning AEs between the different groups. 56 In summary, the substitution of phosphatidylcholine had a positive effect on the clinical situation of patients with UC in a phase II study. However, further studies have to clarify its influence on endoscopic response. Due to its different mechanism of action and excellent safety profile it could be a good supplement to immunosuppressive therapies. However, a recent phase III study using LT-02 in UC was not successful, making it unlikely that this substance will be developed further.
Inhibition of SMAD7: mongersen
Mongersen is a 21-base single-strand antisense oligonucleotide, which binds the mRNA of SMAD7 (= Mothers against decapentaplegic homolog 7) and accelerates its degradation (Table  1) . 48 In patients with CD the expression of SMAD7 in T cells, other lymphocytes and mucosal cells is increased. 66 This is a result of post-transcriptional acetylation by p300, which prevents degradation of SMAD7. 67 SMAD7 inhibits the transforming growth factor (TGF)-β1 signalling pathway downstream of its receptor. 48, 68 The effects of TGF-β1 are predominantly anti-inflammatory. 69 Thus, higher levels of SMAD7 could have a proinflammatory effect ( Figure 2 ). Therefore, it seems reasonable that inhibition of SMAD7 could be a new therapeutic approach in IBD. This idea was supported by experiments in mouse models of colitis. An oligonucleotide accelerated the degradation of SMAD7 mRNA and as a consequence the intestinal inflammation was suppressed. 70 In a phase I study, patients with CD treated with mongersen led to a clinical response. Mongersen was enveloped by acid-ethyl acrylate copolymers, which lead to a release of the active substance in the ileum and the right colon. The release was dependent on the gastrointestinal pH value, which can differ intra-and interindividually. 52 It is postulated that mongersen has a local effect only. This theory is supported by the observation that mongersen was not detectable in the peripheral blood during therapy. 57 In the following phase II randomized, doubleblind, placebo-controlled, multicentre study 166 patients with moderate to severe CD were included ( Table 2 ). 71 Because of pharmacokinetic reasons, patients with lesions at other segments of the gastrointestinal tract than the ileum and the right colon were excluded. As a result of the possible profibrotic effect of TGF-β1, whose signalling pathway is strengthened by mongersen, patients with a history of strictures were not allowed to participate in this study. The primary endpoint of this study was clinical remission. Doses of 10, 40 and 160 mg of mongersen per day were tested. Doses of 40 and 160 mg of mongersen led to significantly higher clinical remission and response rates than placebo therapy. For both these doses of mongersen the frequency of C-reactive protein (CRP) normalization was also significantly better in comparison with the placebo group. A post hoc analysis figured out that patients with higher Crohn's Disease Activity Index (CDAI) scores (>260) reach clinical remission more frequently with 160 mg than 40 mg. However, disease duration and baseline serum CRP had no detectable influence on the therapeutic efficacy of mongersen. 72 There were no relevant differences concerning AEs between the study arms. However, the number of patients and duration of therapy in this study limit the evaluation of safety. A further limitation of this study was the lack of endoscopic assessment. 71 Subsequently, a phase Ib randomized study investigated the endoscopic response in 63 subjects with CD after therapy with 160 mg mongersen for 4, 8 or 12 weeks. The endoscopic response was defined as a reduction in Simple Endoscopic Score for CD (SES-CD) of at least 25% in comparison to baseline. Taking all study arms together the primary endpoint of endoscopic response was reached in 37% of the patients. In the case of high endoscopic activity at baseline (SES-CD > 12), a reduction in SED-CD of at least 25% was observed in 63% of the patients. One great limitation of this study was the lack of a placebo group. 73 Concerning the potential profibrotic effect of mongersen only few data are available. Indeed, the principally profibrotic impact of TGF-β1 has been repeatedly described (chemotactic effect on fibroblasts, stimulation of fibroblast proliferation, increase of collagen synthesis). 74 A small phase I open-label trial without a placebo group examined the influence of mongersen on the development of small bowel strictures. Fourteen patients with CD were treated with mongersen for 7 days and were observed for 6 months. In sonographic controls, no small bowel strictures were detected.
There were no changes in the concentration of markers for CD-related intestinal strictures (e.g. basic fibroblast growth factor). Nevertheless, this study is limited by the very small number of patients and the short duration of therapy. 75 Thus, for patients with lesions in the ileum or right colon 40/160 mg mongersen may reach clinical and possibly endoscopic remission in phase II studies. There was no evidence for relevant AEs, but concerning the risk of fibrosis more clinical data are required. Currently, a phase III study with 40 and 160 mg of mongersen per day is being performed [ClinicalTrials.gov identifier: NCT02641392].
Modulation of sphingosine-1-phosphate receptor: ozanimod
Ozanimod is an agonist of the sphingosine-1-phosphate receptor subtypes 1 and 5 (S1P-R 1/5 ). 76 S1P-R is located on the surface of lymphocytes and is an essential part of the signalling pathway trafficking these cells out of lymph nodes. 77 S1P is built from sphingosine; this reaction is catalysed by sphingosine kinases (SphKs), which can be distinguished as the homologous kinases SphK1 and SphK2, with SphK1 being the main source for S1P. 78 In the gut of patients with UC, an increase in the expression of SphK1 and higher levels of S1P were observed. 78, 79 Thus, this gradient could be important in attracting lymphocytes to the gut. 78, 80 The interaction of ozanimod with S1P-R leads to the internalization of the receptor. Thus, these cells are trapped in the lymph nodes and less lymphocytes are able to migrate into the gut [ Table 1 , Figure 1(a) ]. 78 The S1P-R 1/3/4/5 modulator fingolimod has already been successfully used in the clinical routine of patients with multiple sclerosis. 81 Ozanimod has not only been tested for the therapy of multiple sclerosis, 82 but also for patients with UC. 49 In a randomized, placebo-controlled, doubleblind phase II study, 197 patients with moderately to severely active UC have been tested for efficacy and safety of ozanimod. Different doses were tested (0.5 and 1.0 mg per day) for 8 weeks; the primary endpoint was clinical remission. A significant improvement concerning clinical remission and clinical response was observed for 1 mg ozanimod per day in comparison to placebo. Endoscopic remission was achieved significantly more often in patients from both treatment groups. However, there were no significant differences in histological remission. Frequency and severity of AEs for patients with ozanimod did not differ significantly compared with patients on placebo. However, greater numbers of patients are needed to estimate the safety of this substance more precisely (Table 2 ). 49 Because of these promising results two phase III studies for induction and maintenance therapy, with ozanimod in moderate to severe UC are ongoing [ClinicalTrials.gov identifier: NCT02435992, NCT02531126]. Furthermore, this substance is currently also being tested in patients with CD [ClinicalTrials.gov identifier: NCT02531113]. The therapeutic effect of amiselimod (MT-1303; another modulator of S1P-R 1/5 ) is currently being investigated in patients with CD (phase II) [ClinicalTrials.gov identifier: NCT02389790, NCT02378688]. The modulator of S1P-R 1 etrasimod (APD334) is being used in a phase II study for patients with UC [ClinicalTrials.gov identifier: NCT02536404, NCT02447302].
Inhibition of Janus kinases: tofacitinib and filgotinib
Tofacitinib is an inhibitor of the Janus kinases (JAK) 1/3 and to a lower extent also JAK 2. 50 JAKs are expressed in lymphocytes, granulocytes, macrophages and many nonimmune cell types (e.g. stem cells, epithelial cells). 51 These kinases are critical in a huge number of intracellular signalling pathways, especially for those involved in regulation of immune responses. JAKs are part of the signalling pathway of IL-2, IL-4, IL-6, IL-7, IL-9, IL-12, IL-15, IL-21, interferon (IFN)-γ and further cytokines. 83 JAK targeting has positive effects on psoriasis 84 and rheumatoid arthritis. 85 Therefore, JAK could also be an interesting target for the therapy of IBD (Table 1, Figure 2) . Tofacitinib has already been tested in phase III studies of UC and phase II studies of CD, whereas filgotinib has been used in patients with CD.
In a randomized, double-blind, placebo-controlled, multicentre phase II study 194 patients with moderate to severe UC were treated with tofacitinib for 8 weeks ( Table 2 ). The primary endpoint was clinical response at the end of therapy. The highest dose of tofacitinib (15 mg twice a day) led to a better clinical response than placebo therapy. A statistically significant improvement was observed for clinical remission (for 10 and 15 mg), endoscopic response (for 15 mg) and endoscopic remission (3, 10 and 15 mg). The rate of normalization for calprotectin and CRP was significantly higher after therapy with tofacitinib in comparison to placebo. There were no differences concerning the frequency of AEs or SAEs between placebo and tofacitinib. However, the number of patients was too small for the assessment of a relevant increase of cholesterol levels or the rarely observed mild decrease of the absolute neutrophil count. 58 Two randomized, controlled phase III studies were able to show again significantly better clinical response for 10 mg tofacitinib twice a day in comparison to placebo after 2, 4 and 8 weeks of therapy. In this study AEs and SAEs in general were comparable between the study groups, however increases in cholesterol and creatine kinase were observed in the treatment group (OCTAVE Induction 1 and OCTAVE Induction 2) [ClinicalTrials.gov identifier: NCT01465763, NCT01458951]. 86 Afterwards the efficacy and safety of 5 or 10 mg of tofacitinib as maintenance therapy was tested in these patients (phase III; randomized, placebo controlled). After 52 weeks of maintenance therapy, both doses led to a significant higher proportion of clinical remission and mucosal healing than placebo. Also, the sustained steroidfree remission with tofacitinib was superior to placebo. AEs and SAEs were again similar between the study arms. However, in addition to the already described increase in cholesterol and creatine kinase, a higher rate of herpes zoster was observed in the group with 10 mg tofacitinib (two cases in 23.55 patient years; OCTAVE Sustain) [ClinicalTrials.gov identifier: NCT01458574]. 87 In the associated pharmacokinetic study a stable concentration of the active substance was observed, thus drug-monitoring is not necessary. 88 Furthermore quality of life was significantly improved with both tested doses in comparison to placebo. 89 In a meta-analysis, compromising three placebo-controlled, randomized studies and 1355 patients with UC, a significant improvement in clinical remission, mucosal healing and quality of life were observed after therapy with tofacitinib. There were no differences in SAEs between the drug group and the placebo group. However, the rate of infections was slightly but not significantly increased. Interestingly, a marked therapeutic effect was seen in patients previously treated with anti-TNF antibodies. 90 Tofacitinib has also been tested in patients with moderate to severe CD. A total of 139 patients were included in a randomized, double-blind, placebo-controlled, multicentre phase II study. The primary endpoint was the proportion of clinical responders after 4 weeks of therapy. Concerning clinical response and clinical remission, no differences between placebo and tofacitinib were observed. CRP and calprotectin decrease under therapy with 15 mg tofacitinib two times per day, but statistical significance was not determined. The number of AEs and SAEs did not differ significantly between those patients receiving tofacitinib and those in the placebo group. However, there was a dose-dependent increase in cholesterol (high-density lipoprotein and low-density lipoprotein) levels with tofacitinib. 59 In a further phase II study, 5 and 10 mg tofacitinib two times per day for 8 weeks of induction and 26 weeks of maintenance were compared with placebo in patients with CD. A positive tendency in clinical outcome was observed in the 10 mg group, but without being statistically significant. However, the decrease in CRP in comparison to baseline was highly significant [ClinicalTrials.gov identifier: NCT01393626, NCT01393899]. 91 In a followup open-label long-term extension phase IIb study based on 150 patients from the NCT01393899 study no further safety findings were observed during an additional 42 weeks of therapy [ClinicalTrials.gov identifier: NCT01470599]. 92 In summary, tofacitinib improved clinical activity and the endoscopic situation in patients with UC. It is suitable for induction and maintenance of remission. In CD, however, convincing data on clinical efficacy are still lacking.
Filgotinib is a specific inhibitor of JAK 1. Although the inhibition is limited to fewer cytokine receptors, there is still a pleiotropic anti-inflammatory effect through inhibition of the signalling pathways of IL-2, IL-6, IFN-γ, among others (Table 1) . 50 In a randomized, placebo-controlled, doubleblind phase II study of 174 patients with moderately to severely active CD, the efficacy and safety of filgotinib were tested ( Table 2) . A dose of 200 mg filgotinib was administered once a day for 10 weeks, and the primary endpoint was clinical remission. After 10 weeks of initial therapy the patients were again randomized (placebo, 100 mg filgotinib, 200 mg filgotinib). Treatment with filgotinib significantly improved clinical remission and response in comparison to placebo. However, no significant differences concerning endoscopic response were observed. CRP was decreased more in the filgotinib group than in the placebo group. There were indications of an increased risk of infections in the treatment group. 55 Thus, filgotinib is able to improve clinical activity in patients with CD in a phase II study, but further studies have to investigate the impact on the endoscopic/histological situation and the potential risk for infections.
Synthesis and outlook
Treatment of IBD has made great progress in the last decades, especially by developing biologicals like TNFα inhibitors. 1, 2 However, in a notable proportion of patients with IBD, the therapy is not able to induce clinical remission or control inflammation sufficiently. 33 The systemic immunosuppressive effect may be associated with SAEs. 34, 93 Therefore, many new drugs are presently being tested in clinical trials. In addition to subcutaneous and intravenous substances, many oral drugs are now approaching regular clinical application. 33 Due to the discomfort during application of parenteral substances, oral drugs are often better accepted by patients. 94 However, the intake is not so well controlled. Moreover, in patients with CD in whom the small intestine is affected, oral substances are possibly not sufficiently absorbed. From 8% to 60% of patients with IBD develop antibodies against infliximab, which can lead to a secondary loss of efficacy. 95 There is hope that immunogenicity is not (or at least more seldom) observed for orally administered small inhibitors. Due to a shorter interval of intake it can be assumed that oral drugs can reach more stable concentration over time, which could support a favourable ratio between efficacy and adverse events. This ratio can be further improved by a locally restricted distribution and effect (e.g. mongersen, phosphatidylcholine). 56, 48 AJM300, 35 ozanimod, 49 LT-02 56 and tofacitinib 58 have been used in patients with UC in clinical trials. For all substances, a statistically significant improvement in comparison to placebo has been observed for clinical response in phase II studies. A significant positive effect on clinical remission and endosopic remission was shown for all substances except LT-02. AJM300 led to a histological response, whereas ozanimod and LT-02 failed to reach histological remission. For tofacitinib no histological assessment was performed. In clinical trials using AJM300, ozanimod or LT-02 the adverse effects did not differ significantly compared with the placebo groups. AJM300's mechanism of action makes triggering of PML possible. 45, 46 This complication has not been observed after therapy with AJM300 so far. However, the number of patients is too small to rule out this effect. 45 For tofacitinib, increases in creatinine kinase, cholesterol and rate of herpes zoster 90 were described. In summary, all four substances showed acceptable ratios between efficacy and safety. Currently, the data are most robust for tofacitinib (the only substance with published positive data from a phase III study). 89 For CD, mongersen, 71 tofacitinib 91 and filgotinib 55 have been tested in clinical trials. Tofacitinib failed to significantly improve clinical response or remission in patients with CD. An endosopic evaluation was not performed.
Both filgotinib and mongersen were superior to placebo in clinical response and clinical remission. Filgotinib did not lead to an improved endoscopic response or remission. A controlled endoscopic or histological assessment was not performed for mongersen. Whereas filgotinib could be associated with an elevated risk of infections, mongersen was not associated with an increased rate of SAEs or AEs. This agrees with the assumption that mongersen is released at the ileum and right colon without having relevant systemic effects. 57 Indeed, further studies have to investigate the possible profibrotic effect of mongerson. 74 An unfavourable effect of the currently available formulation is the inability to reach lesions on the other sides of the gastrointestinal tract or extraintestinal manifestations. In summary, mongersen might be a reasonable approach for the treatment of patients with lesions in the ileum or right colon. Filgotinib could be more suitable for systemic immunosuppression in patients with CD. The differences concerning clinical outcome of filgotinib and tofacitinib could result from the more selective mechanism of action of filgotinib. This might allow a higher dose of the active substance and thus lead to a greater therapeutic effect (tofacitinib: 10/20 mg/day, molar mass: 312 g/mol; filgotinib: 200 mg/day, molar mass: 425 g/mol). However, pharmacokinetic aspects and differences concerning patient populations might also play a role.
It is important to emphasize the limited possibility of comparing such substances without data from head-to-head studies. We are optimistic that some of these drugs will reach clinical approval and improve control of inflammatory activity and life quality.
Improvements have not only been made in active substances but also in drug coatings and specific formulations. 94 In the case of budesonide and mesalamine, but also the new substances mongersen and LT-02, a pH-dependent release at certain locations of the gastrointestinal tract has already been successfully realized. 52, 96, 97 In addition to this, the use of nanotherapeutics could increase accumulation of the active substance at the side of inflammation and improve cellular uptake. 94, 98 A phase II trial compared a delayedrelease formulation of 6-MP (DR-6MP) with purinethol in patients with CD. 99 The systemic bioavailability of DR-6MP was negligible. This formulation was well tolerated and the frequency of AEs was significantly lower than with purinethol. Furthermore, the combined primary endpoint of clinical response and clinical remission was similar for purinethol and DR-6MP. However, the time until maximal clinical response was shorter with DR-6MP. Thus, the ratio between efficacy and adverse reactions of known substances could be improved by optimizing their formulation. These new release strategies could also be the foundation for new oral and locally effective immunosuppressive agents (e.g. orally administered anti-CD3 antibodies). 100 A suitable coating of processed stool could enable an oral faecal microbiome transfer, which simplifies the realization of this method. Encapsulated stool was successfully tested in patients with Clostridium difficile infection. 101 So far, the data for (endoscopically applied) faecal microbiome transfer in UC are contradictory. 102, 103 For tofacitinib a new formulation has been designed which reduces the number of intakes per day (one per day versus two per day before). This could enhance therapy adherence. 54 In addition, adherence monitoring will become increasingly important for orally administered drugs. For some drugs with relevant absorption, such as the orally administered thiopurines 104 or tofacitinib, 54 it is already possible to measure their concentrations in patients' blood.
Conclusion
Despite the introduction of biologicals in the last years, disease activity in a relevant number of patients is still not sufficiently under control. Therefore, there is a need for new therapeutic approaches. Fortunately, there are a lot of promising drugs in the pipeline. The oral substances AJM300, filgotinib, LT-02, mongersen, ozanimod and tofacitinib have been successfully tested in (at least) phase II trials for the therapy of patients with IBD. In addition to this, new formulations have been developed, which could improve the efficacy and safety of established drugs or enable the application of new substances. Thus, we have to await the (final) results of phase III studies and hope for substantial improvements in the therapy of IBD.
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